tbuckley/cabot-search huggingface dataset:
Plasma level of tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) reflects functional cardiovascular abnormalities in essential hypertension Joanne Moncrieff, M. M. Lindsay, Andrew D. McGavigan, Paul R. Maxwell, John M. C. Connell, Francis G. Dunn. Stobhill Hospital, Glasgow, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
Bulletin of New York Acad of Medicine
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letter to the Editor: Differentiating Between Intentional Versus Unintentional Weight Loss
Authors: Leah Puklin, Melinda L. Irwin, Tara Sanft, Leah M. Ferrucci
Journal: Journal of the National Comprehensive Cancer Network (2022)

We read with particular interest the article by Martel et al 1 exploring associations between obesity, weight change, and survival in patients with HER2-positive early breast cancer in the ALTTO trial.The authors main findings were 2-fold: (1) obesity at randomization was associated with worse distant disease-free survival (DDFS) and overall survival (OS), and (2) weight loss $5% at 2 years after randomization was associated with poorer DFS, DDFS, and OS.Although the first finding is consistent with previously published metaanalyses, 2 we have concerns regarding the authors' discussion of the second result and believe a more thorough explanation is warranted to minimize misinterpretations that could negatively impact clinical recommendations.The authors noted that intentional versus unintentional weight loss would have been informative for this study, but was unavailable.We wanted to clarify that not differentiating between how weight loss was achieved is a crucial missing data point that ultimately obscures their conclusion.Weight loss after diagnosis among patients with breast cancer, induced by healthy diet and exercise, has favorably impacted treatment-related adverse effects, quality of life, body composition measures, and serum inflammatory and
ABSTRACTS
Authors: None &NA;
Journal: Clinical Nuclear Medicine (1990)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Online First Collections ACNM MeetingsCMECommunication in OrganizationCOVID-19Feedback and RewardsFrom the American College of Nuclear MedicineHighly Cited and Frequently Read ArticlesPlanning and Conducting Meetings EffectivelyQuality and Safety in Health CareRecruitment of New PhysiciansTips for Giving a Memorable PresentationTips for LeadersTips for Physicians in Getting the Right Job ACNM ArticlesACNM Website For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Tissue Repair
Authors: Walter R. Benson
Journal: JAMA (1969)

The author has succeeded well in producing a basic introductory text on tissue repair and regeneration. On most subjects he provides a short historical review, but the main emphasis is on recent studies and discoveries. He gives the two or more views on debatable subjects and points out areas where present knowledge is insufficient to reach a conclusion. The text is excellent, except for a few instances where his brevity leads almost to cryptography. The excellent illustrations range from diagrammatic sketches to electron micrographs. The large bibliography contains pertinent non-English references, although the majority are of United Kingdom or US origin. The author index alone occupies 34 pages. The contents of the 12 chapters vary in quality and quantity, dependent to a large extent upon the published work available on a subject. However, the author is also responsible for some unevenness. The material on the testes occupies only one page
Outcome of preoperative concurrent radiation and infusional gemcitabine in locally advanced rectal cancer, a phase 2 trial.
Authors: Shouki Bazarbashi, Ahmed Mostafa Gad, Ahmed Ali Badran, Mahmoud Elshenawy, Ali H Aljubran, Ahmad Al Zahrani, Hadeel Al Manae, Abdullah Alsuhaibani, Ahmed Elashwah, Mohammed Neimatallah, Alaa Abdul Jabbar, Luai Ashari, Samar Al Homoud, Hazem Ghebeh, Nasser Alsanea, Mohammed Mohiuddin
Journal: Journal of Clinical Oncology (2022)

94 Background: The achievement of a pathological complete response with preoperative concurrent chemoradiotherapy in locally advanced rectal cancer has been found to correlate with a reduced incidence of local and distant recurrences. With the radiosensetizing properties of gemcitabine, we tested the efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal cancer. Methods: This was a phase II, single-arm, single-institution trial. Eligibility included a diagnosis of rectal adenocarcinoma with stage T2–4 and/or nodal involvement by MRI and endoscopic rectal ultrasound, age ≥ 18 years and no prior chemotherapy or radiotherapy. Patients received preoperative radiation at a dose of 50.4–54 Gy over 28 days with concurrent infusional gemcitabine administered at a dose of 100 mg/m2 over the course of 24 hours weekly for 6 weeks. The primary endpoint was a pathological complete response (pCR). The trial was registered at clinicaltrials.gov (NCT02919878). Results: Forty patients were enrolled in the study. All of the patients completed the planned therapy, except for one patient who died at the end of his concurrent chemoradiation. Eight patients did not undergo surgery, with 1 patient dying (mentioned above), 2 patients progressing to nonresectable disease and 5 patients withdrawing consent. Six patients progressed prior to or had metastases identified at surgery, with 2 patients having unresectable metastases, 3 patients having resectable liver metastases and 1 patient having a peritoneal metastasis (not resected). Serious adverse events were reported in 8 patients (20%). The most common grade 3–4 toxicities in the preoperative period included lymphopenia (50%), neutropenia (41%), anemia (15%), diarrhea (12%), abdominal pain (12%) and proctitis (8%). Out of the 32 patients who underwent surgery, 7 patients achieved pCR at a rate of 20%. With a median follow-up of 30 months, 4 additional patients relapsed (all of these patients had distant metastases, with one subsequently having a local recurrence). The 3-year event-free and overall survival rates were 70% and 85%, respectively. Conclusions: Concurrent preoperative chemoradiotherapy using infusional gemcitabine for locally advanced rectal cancer achieved an encouraging local control. Distant metastasis remains not decreased. Further investigations of a preoperative regimen containing gemcitabine is warranted. Clinical trial information: NCT02919878.
Therapeutics in the Pipeline Targeting<i>α</i>-Synuclein for Parkinson's Disease
Authors: Hilary Grosso Jasutkar, Stephanie E. Oh, M. Maral Mouradian
Journal: Pharmacological Reviews (2022)

Parkinson9s disease (PD) is the second most common neurodegenerative disorder and the fastest growing neurologic disease in the world, yet no disease-modifying therapy is available for this disabling condition. Multiple lines of evidence implicate the protein <i>α</i>-synuclein (<i>α</i>-Syn) in the pathogenesis of PD, and as such, there is intense interest in targeting <i>α</i>-Syn for potential disease modification. <i>α</i>-Syn is also a key pathogenic protein in other synucleionpathies, most commonly dementia with Lewy bodies. Thus, therapeutics targeting this protein will have utility in these disorders as well. Here we discuss the various approaches that are being investigated to prevent and mitigate <i>α</i>-Syn toxicity in PD, including clearing its pathologic aggregates from the brain using immunization strategies, inhibiting its misfolding and aggregation, reducing its expression level, enhancing cellular clearance mechanisms, preventing its cell-to-cell transmission within the brain and perhaps from the periphery, and targeting other proteins associated with or implicated in PD that contribute to <i>α</i>-Syn toxicity. We also discuss the therapeutics in the pipeline that harness these strategies. Finally, we discuss the challenges and opportunities for the field in the discovery and development of therapeutics for disease modification in PD. <h3>Significance Statement</h3> PD is the second most common neurodegenerative disorder, for which disease-modifying therapies remain a major unmet need. A large body of evidence points to <i>α</i>-synuclein as a key pathogenic protein in this disease as well as in dementia with Lewy bodies, making it of leading therapeutic interest. This review discusses the various approaches being investigated and progress made to date toward discovering and developing therapeutics that would slow and stop progression of these disabling diseases.
Teleology first: Goals before knowledge and belief
Authors: Tobias Schlicht, Johannes L Brandl, Frank Esken, Hans-Johann Glock, Albert Newen, Josef Perner, Franziska Poprawe, Eva Schmidt, Anna Strasser, Julia Wolf
Journal: Behavioral and Brain Sciences (2021)

Abstract Comparing knowledge with belief can go wrong in two dimensions: If the authors employ a wider notion of knowledge, then they do not compare like with like because they assume a narrow notion of belief. If they employ only a narrow notion of knowledge, then their claim is not supported by the evidence. Finally, we sketch a superior teleological view.
The Spirit of Revolt
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P303: Racial Differences in the Associations Between Food Insecurity and Fibroblast Growth Factor 23 (FGF23) in The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Authors: Lindsay R Pool, Kiarri N Kershaw, Samantha E Montag, Penny Gordon-Larsen, Orlando M Gutiérrez, Jared P Reis, Tamara Isakova, Myles Wolf, Mercedes R Carnethon
Journal: Circulation (2018)

Introduction: Elevated Fibroblast Growth Factor 23 (FGF23) - an endocrine hormone linked to cardiovascular and kidney disease outcomes - is a compensatory response to high dietary phosphate load or chronic kidney disease. Large quantities of inorganic phosphates additives are found in processed foods, and food insecurity is associated with higher consumption of processed foods. Hypothesis: We hypothesized that developing food insecurity is associated with an increase in FGF23. Methods: We included CARDIA study participants with a stored plasma sample available from at least two consecutive exams at years 20, 25, and 30 (N=3,421). Food insecurity was assessed through a single question about ability to afford quantity and quality of food. FGF23 levels were assessed using a commercial c-terminal ELISA. Due to a strong right skew in FGF23 levels, we divided FGF23 in quartiles and compared the highest quartile to the combined lower three quartiles using logistic regression. Econometric fixed effects models that adjust by design for all time-invariant covariates were used to model the longitudinal association between simultaneous within-person change in food insecurity and FGF23. Due to an interaction between food insecurity and race ( p =0.002), we stratified by race. Results: About 29% of blacks and 14% of whites experienced change in food insecurity during follow-up. Developing food insecurity was associated with a 1.46 greater odds of increasing to the highest quartile of FGF23 (95% CI: 1.02,2.10) among blacks; however, there was no significant longitudinal association among whites (OR=1.05; 95% CI: 0.62,1.77). Conclusions: Using models that tightly control for all time-invariant confounding, we found that developing food insecurity was associated with increases in FGF23 among blacks. The differential increases in blacks as compared to whites may be due to differences in dietary changes in response to developing food insecurity. Previous research has shown racial differences in dietary quality by food insecurity.
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Authors: Liye Zhou, Zexian Zeng, Ann Marie Egloff, Fan Zhang, Fei Guo, Katie M Campbell, Peter Du, Jingxin Fu, Paul Zolkind, Xiaojing Ma, Zhe Zhang, Yi Zhang, Xiaoqing Wang, Shengqing Gu, Rachel Riley, Yasutaka Nakahori, Joshua Keegan, Robert Haddad, Jonathan D Schoenfeld, Obi Griffith, Robert T Manguso, James A Lederer, X Shirley Liu, Ravindra Uppaluri
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Immune checkpoint blockade (ICB) response in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) is limited to 15%–20% of patients and underpinnings of resistance remain undefined. Methods Starting with an anti-PD1 sensitive murine HNSCC cell line, we generated an isogenic anti-PD1 resistant model. Mass cytometry was used to delineate tumor microenvironments of both sensitive parental murine oral carcinoma (MOC1) and resistant MOC1esc1 tumors. To examine heterogeneity and clonal dynamics of tumor infiltrating lymphocytes (TILs), we applied paired single-cell RNA and TCR sequencing in three HNSCC models. Results Anti-PD1 resistant MOC1esc1 line displayed a conserved cell intrinsic immune evasion signature. Immunoprofiling showed distinct baseline tumor microenvironments of MOC1 and MOC1esc1, as well as the remodeling of immune compartments on ICB in MOC1esc1 tumors. Single cell sequencing analysis identified several CD8 +TIL subsets including Tcf7 +Pd1− (naïve/memory-like), Tcf7 +Pd1+ (progenitor), and Tcf7-Pd1+ (differentiated effector). Mapping TCR shared fractions identified that successful anti-PD1 or anti-CTLA4 therapy-induced higher post-treatment T cell lineage transitions. Conclusions These data highlight critical aspects of CD8 +TIL heterogeneity and differentiation and suggest facilitation of CD8 +TIL differentiation as a strategy to improve HNSCC ICB response.
Prilocaine-Induced Methemoglobinemia— Wisconsin, 1993
Journal: JAMA (1994)

Methemoglobinemia is an uncommon disorder in which hemoglobin is not oxidized and not capable of binding oxygen. This condition may be associated with exposure to nitrate-contaminated drinking water, aniline dyes, and amide-containing medications. Ortho-toluidine, a metabolite of the anesthetic prilocaine, also can induce this condition (1). During March-August 1993, three Wisconsin women treated by the same oral surgeon developed methemoglobinemia after being injected with a prilocaine-based local anesthetic. The surgeon notified the Division of Health, Wisconsin Department of Health and Social Services, of these cases 1 week after the third case occurred. This report summarizes the case investigations.
Modified FOLFIRINOX (mFOLFIRINOX) in high risk locally advanced rectal adenocarcinomas.
Authors: Ramjas Prajapati, Sujay Srinivas, Vikas S Ostwal, Prabhat Ghanshyam Bhargava, Reena Engineer, Rahul Krishnatry, Zoya Peelay, Ashwin Luis Desouza, Avanish Saklani, Suman Kumar Ankathi, Manali Parulekar, Anant Ramaswamy
Journal: Journal of Clinical Oncology (2022)

108 Background: There is limited data with regard to the use of modified 5-fluoroural-leucovorin-irinotecan-oxaliplatin (mFOLFIRINOX) in enabling resection and increasing survival of locally advanced rectal adenocarcinomas (LARC) with high-risk characteristics (T4b status, signet ring histology, etc.) post standard neoadjuvant long course chemoradiation (NACTRT) or short course radiation (SCRT) and chemotherapy. Methods: Patients with LARC from January 2018 to December 2020 receiving mFOLFIRINOX (5-Fluorouracil - 1800mg/m2 over 46 hours, Leucovorin 300mg, Irinotecan 135mg/m2, oxaliplatin 65mg/m2) post NACTRT/SCRT to facilitate curative local resection were evaluated. The primary endpoint was event free survival (EFS), where event was defined as disease progression or recurrence post resection after mFOLFIRINOX. Survivals were calculated using Kaplan-Meier analysis. Results: Forty-seven patients were evaluated with a median age of 33 years (Range:18-59), 45% T4b status, 94% radiological circumferential margin (CRM) involved (79% CRM positive post NACTRT/SCRT), 43% extramural venous invasion (n=33) and 36% signet ring histology. 62% had received prior NACTRT and 38% had received SCRT with chemotherapy before receiving mFOLFIRINOX. The most common grade 3 and grade 4 treatment related side effects included diarrhoea (7%), anaemia (4%) and infections (4%). Intended duration of mFOLFIRINOX or beyond was completed in 94% of patients. 60% of patients underwent curative local resection with R0 resection rates of 100% (n=28) and pathological complete response rates of 21%. The most common surgeries done were exenterations and abdominoperineal resections in 22% and 17% patients respectively. With a median follow up of 19 months, 25 patients had recurred or progressed for a median EFS of 20 months [95% confidence interval (CI): 15-24] while median overall survival was 55 months (95% CI: 24-86). Conclusions: Locally advanced rectal cancers with high-risk characteristics are a niche group of cancers with less-than-optimal outcomes post standard neoadjuvant strategies. mFOLFIRINOX appears to be well tolerated in this cohort of patients and enables conversion to curative local resection and potentially improves survival as well.
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort—A BIOMECA Consortium Study
Authors: Timothy A Ritzmann, Rebecca J Chapman, John-Paul Kilday, Nicola Thorp, Piergiorgio Modena, Robert A Dineen, Donald Macarthur, Conor Mallucci, Timothy Jaspan, Kristian W Pajtler, Marzia Giagnacovo, Thomas S Jacques, Simon M L Paine, David W Ellison, Eric Bouffet, Richard G Grundy
Journal: Neuro-Oncology (2022)

SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3-21 years treated with a staged management strategy. A further aim was to assess the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide, and cyclophosphamide (VEC). We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers.
JAMA Reference Directories
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of a new HIV-1 intersubtype circulating recombinant form (CRF123_0107) in Hebei province, China
Authors: Ying Xing, Lijing Wang, Yating Li, Yuling Wang, Leilei Han, Guiqin Huang, Jingwan Han, Wenjun Zhang, Lei Jia, Yongjian Liu, Xiaolin Wang, Tianyi Li, Jingyun Li, Li Yang, Xiaojing Qu, Yingxia Li, Erhei Dai, Hanping Li, Lin Li
Journal: Journal of Infection (2022)
Calcineurin inhibition with cyclosporin A preserves heart function by decreasing apoptosis Lieven Pool, Thomas N. Masters, Alexander Fokin, Miroslav Barancik, Tibor Ziegelhoeffer, Francis Robicsek, Jutta Schaper. Max-Planck-Institute, Bad Nauheim, Germany, Heineman Medical Research Center, Charlotte, NC
Journal: Journal of the American College of Cardiology (2001)
SARATOGA MEETING.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal